There are currently several anti-PD-(L)1 therapy schemas in various advanced cancers (Balar et al. 2017; Borghaei et al. 2015; Brahmer et al. 2015; Gandhi et al. 2018; Hellmann et al. 2019; Herbst et al. 2016; Horn et al. 2018; Motzer et al. 2018,2015; Reck et al. 2016; Rini et al. 2019; Rittmeyer et al. 2017; Robert et al. 2015a, b) with similar treatment outcomes and toxicity profiles, yet, small subgroups of patients such as advanced NSCLC patients with PD-L1 expression ≥ 50% treated in first line, or tumors with MSI status seem to benefit more from specific therapies. The gene discussed is CD274; the disease is cancer.